Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00353912
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2006-07-17
Brief Title:
Efficacy Safety of Orally Administered ValsartanAmlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 12-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered ValsartanAmlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartanamlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients MSSBP 160 mmHg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None